L3VLUP
ProSign in

NMRA · AMGN in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

NMRAAMGN
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • NMRA
  • AMGN
0102030202120222023202420252026
Holders and value by quarter
QuarterNMRAAMGN
Q3 2020none listed holders, n.a.16 holders, $16.3bn
Q4 2020none listed holders, n.a.19 holders, $14.0bn
Q1 2021none listed holders, n.a.16 holders, $14.5bn
Q2 2021none listed holders, n.a.23 holders, $13.8bn
Q3 2021none listed holders, n.a.24 holders, $11.6bn
Q4 2021none listed holders, n.a.21 holders, $10.4bn
Q1 2022none listed holders, n.a.23 holders, $9.9bn
Q2 2022none listed holders, n.a.28 holders, $9.7bn
Q3 2022none listed holders, n.a.21 holders, $7.9bn
Q4 2022none listed holders, n.a.24 holders, $9.3bn
Q1 2023none listed holders, n.a.22 holders, $8.4bn
Q2 2023none listed holders, n.a.26 holders, $7.4bn
Q3 20231 holders, $141k26 holders, $8.7bn
Q4 2023none listed holders, n.a.24 holders, $8.4bn
Q1 2024none listed holders, n.a.25 holders, $6.7bn
Q2 20241 holders, $1.6m20 holders, $8.0bn
Q3 20241 holders, $4.1m21 holders, $8.8bn
Q4 20242 holders, $6.4m20 holders, $8.2bn
Q1 2025none listed holders, n.a.25 holders, $12.0bn
Q2 2025none listed holders, n.a.20 holders, $10.2bn
Q3 2025none listed holders, n.a.17 holders, $10.4bn
Q4 2025none listed holders, n.a.19 holders, $18.0bn
Q1 2026none listed holders, n.a.15 holders, $21.4bn
Q2 2026none listed holders, n.a.23 holders, $24.9bn
NMRA

Neumora Therapeutics Inc.

Holders
0
Reported value
$0
Buyers
n.a.
Sellers
n.a.

No cross-section for this quarter.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP
AMGN

Amgen Inc

Holders
25
Reported value
$12.0bn
Buyers
10
Sellers
16

Breadth -6 among 95 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP

Who holds both, Q1 2025

Among the 25 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Both (0)

No tracked manager lists every one of them.

Only NMRA (0)

None.

Only AMGN (25)

Acadian Asset Management LLC, AllianceBernstein LP, ARK Investment Management LLC, Brevan Howard Capital Management LP, Capital Research Global Investors, Capital World Investors, Caxton Associates LLP, D. E. Shaw & Co., Dodge & Cox, Fidelity (FMR LLC), Hudson Bay Capital Management LP, Invesco Ltd, Janus Henderson Group Ltd, Man Group PLC, Marshall Wace LLP, Neuberger Berman Group LLC, PDT Partners LLC, Renaissance Technologies LLC, Squarepoint Ops LLC, T. Rowe Price Associates Inc, Tudor Investment Corp, Two Sigma Advisers LP, Two Sigma Investments LP, Winton Group Ltd, Woodline Partners LP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →